期刊文献+

PSA及其相关指标在前列腺癌中的应用 被引量:1

下载PDF
导出
摘要 前列腺特异性抗原(prostate specific antigen,PSA)是目前已知的最有效的前列腺肿瘤标志物,现已广泛应用于前列腺癌的早期检测、术后疗效评估以及指导补救措施。本文就PSA及其分子衍生物的相关指标做一总结。1 PSA的生物学特性1979年由Wang等用免疫沉淀法首次成功地从人前列腺组织中提纯出PSA蛋白。自1987年Stamey等发现血清PSA水平与前列腺癌体积有关以来,PSA便作为前列腺肿瘤标记物广泛应用于临床。PSA是一种由前列腺柱状上皮细胞和尿道周围腺体产生的一种丝氨酸蛋白水解酶,由含240个氨基酸的多肽链组成,分子量约为33000~34000D,其基因位于19号染色体。其主要功能为快速分解精囊分泌的精液凝固结构蛋白,使射精后的精液凝块液化,提高精子活动性。PSA具有组织特异性。
出处 《泌尿外科杂志(电子版)》 2010年第2期1-4,共4页 Journal of Urology for Clinicians(Electronic Version)
  • 相关文献

参考文献20

  • 1杭永贵,孙晓文.前列腺癌基因3(PCA3)与前列腺癌的研究进展[J].现代泌尿外科杂志,2009,14(5):400-402. 被引量:6
  • 2刘东亮,卢一平.PSA及其分子形式与PSAD、PSAV、PSAT在前列腺癌早期诊断中的应用[J].华西医学,2003,18(4):591-592. 被引量:5
  • 3李颂.PSA及其相关指标的应用[J].国外医学(泌尿系统分册),1998,18(4):168-170. 被引量:3
  • 4杨立.游离PSA对前列腺癌检测的新进展[J].国外医学(泌尿系统分册),1998,18(2):52-54. 被引量:18
  • 5Miller JI,,Ahmarm FR,Drach GW,et al.The clinical usefulness of serum prostate specific antigen after hormonaltherapy of metastatic prostate cancer. Journal d Urologie . 1992
  • 6Mulders PF,Fernandez MP,Theeuwes AC,et al.Value of biochemical markers in the management of disseminated prostatic cancer. European Urology . 1992
  • 7Raaijmakers R,Wildhagen M F,Ito K, et al.Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.. Urology . 2004
  • 8Benson MC,Ring KS,Olsson CA.The determination of stage D-O carcinoma of the prostate using PSA density. . 1989
  • 9Wang,TJ,Slawin,KM,Rittenhouse,HG.Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. European Journal of Biochemistry . 2000
  • 10Vessella RL,Lange PH,Partin AW,et al.Probability of prostate cancerdetectionbased on results of a multicenter study using the AxSYMfreePSA and total PAS assay. Urology . 2000

二级参考文献16

  • 1VAN GILS MP, STENMAN UH, SCHALKEN JA, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project [J]. Eur Urol, 2005, 48(6):1031-1041.
  • 2BUSSEMAKERS MJ, VAN BOKHOVEN A, VERHAEGH GW, et al. DD3: a new prostate-specific gene highly overexpressed in prostate cancer [J]. Cancer Res, 1999, 59(23) :5975- 5979.
  • 3DE KOK JB, VERHAEGH GW, ROELOFS RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors [J]. Cancer Res, 2002, 62(9) :2695-2698.
  • 4HESSELS D, KLEIN GUNNEWIEK JM, VAN OORT I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer [J].Eur Urol, 2003, 44(1):8216.
  • 5LANDERS KA, BURGER MJ, TEBAY MA, et al. Use of multiple biomarkers for amolecular diagnosis of prostate cancer [J]. Int J Cancer, 2005, 114(6):950-956.
  • 6DERAS IL, AUBIN SM, BLASE A, et al. PCA3, A molecular urine assay for predicting prostate biopsy outcome[J]. Urology, 2008, 179(4)..1587-1592.
  • 7VOLLMER RT. Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule [J]. Am J Clin Pathol, 2006, 125(3) :336-342.
  • 8ROEHL KA, ANTENOR JA, AND CATALONA WJ. Serial biopsy results in prostate cancer screening study [J]. J Urol, 2002, 167(6) :2435-2439.
  • 9MARKS LS, FRADET Y, DERAS IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy[J]. Urology, 2007, 69(3):532-535.
  • 10MOTTET N, SCHALKEN JA, HEIDENREICH A, et al. Highlights on prostate cancer from Urological and Oneologieal Congresses in 2007 [J].Eur Urol, 2008, 7(6):460-476.

共引文献29

同被引文献36

  • 1卢慕峻,姚德鸿,蒋跃庆,董国勤,王忠,鲍泳扬,金嘉萍,林梅绥.新型肿瘤标记物P504S对前列腺癌诊断的价值[J].中国男科学杂志,2005,19(3):28-30. 被引量:3
  • 2高宝辉,谢丽微,陈映鹤.前列腺腺癌组织中p53和P504S的表达及意义[J].山东医药,2006,46(4):60-61. 被引量:4
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics,2008 [ J]. CA Cancer J Clin, 2008,58(2) :71-96.
  • 4Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen [ J ]. Invest Urol, 1979,17 ( 2 ) : 159-163.
  • 5Starney TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate [ J ]. N Engl J Med, 1987,317(15) : 909-916.
  • 6Ercole C J, Lange PH, Mathisen M, et al. Prostatic specific anti- gen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer [ J]. J Urol, 1987, 138 ( 5 ) : 1181-1184.
  • 7Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy [ J ]. JAMA, 1999,281 (17) :1591-1597.
  • 8Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of pros- tate-specific antigen in serum as a screening test for prostate cancer [J]. NEnglJMed, 1991,324(17):1156-1161.
  • 9Makarov DV, Loeb S, Getzenberg RH, et al. Biomarkers for pros- tate cancer[J]. Annu Rev Med, 2009(60) :139-151.
  • 10Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of pros-tate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter[J]. N Engl J Med, 2004, 350(22): 2239-2246.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部